Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2325

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 4
Chunk 2325
---
563) 
     (42,057,695)
  
    Total liabilities, convertible preferred stock and stockholders’ deficit 
    $6,206,929
    $5,126,302 

See
accompanying notes to the consolidated financial statements

Reflects a 1-for-100 reverse stock split effective
January 8, 2025

F-3

CERO THERAPEUTICS HOLDINGS, INC.

CONSOLIDATED
STATEMENTS OF OPERATIONS

    For the 
period from 
February 14, 
2024 through 
December 31,
 2024  
    For the
 period from 
January 1, 
2024 through 
February 13,
 2024  
    For the
 year ended
December 31,
 2023 

    (Successor)  
    (Predecessor)  
    (Predecessor) 
  
    Operating expenses: 

    Research and development 
    $6,315,552  
    $764,192  
    $5,288,580 
  
    General and administrative 
     8,985,351  
     132,941  
     2,386,469 
  
    Total operating expenses 
     15,300,903  
     897,133  
     7,675,049 
  
    Loss from operations 
     (15,300,903) 
     (897,133) 
     (7,675,049)

    Other income (expenses): 

    Gain from settlement of liabilities with vendors 
     3,339,223  
     -  
     8,144 
  
    Other expenses 
     (672,378) 
     -  
     (62,182)
  
    Change in fair value of earnout and derivative liabilities 
     4,880,000  
     320,117  
     301,170 
  
    Interest income, net 
     21,846  
     4,805  
     138,340 

    Total other income, net 
     7,568,691  
     324,922  
     385,472 

    Net loss 
     (7,732,212)
     (572,211) 
     (7,289,577)

    Deemed dividend - preferred stock